Please assess the completion status of the following clinical trial:

Trial Title: ITACA-S2 (Intergroup Trial in Adjuvant Chemotherapy for Adenocarcinoma of the Stomach)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* age \>18 years~* Eastern Cooperative Oncology Group - Performance Status (ECOG-PS) 0-1~* T3 or T4 carcinoma without lymphnode involvement (N0) and any T-stage with (N+) lymphnode involvement~* no distant metastases (M0)~* fitness to receive CHT and CHT-RTX~* no peripheral neuropathy greater than grade 1~* absence of peritoneal carcinomatosis~* written informed consents (one for each trial) given before the randomization, according to International Conference on Harmonisation/Good Clinical Practice (ICH/GCP)~Exclusion Criteria:~* adenocarcinoma of the gastro-esophageal junction~* previous CHT or RTX~* abnormal haematological, hepatic or renal functions, assessed within 7 days prior to randomization~* lymphnode metastases (biopsy proof, if possible) outside the loco-regional field, such as supraclavicular, mediastinal or para-aortic nodes~* positive peritoneal cytology~* clinical significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (≤ 6 months), myocardial infarction (≤ 6 months), instable angina, New York Heart Association grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication~* lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication~* history or presence of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or patients at high risk from treatment complications~* pregnancy or breast feeding. Women of childbearing potential and their parents must be willing to practice acceptable methods of birth control to prevent pregnancy~* presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and f-up schedule

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- peri-operative CHT (Arm A) (Type: EXPERIMENTAL): In peri-operative CHT arm CHT will be administered within 1 week (+3 days) after randomization, surgery will be performed after re-staging and 3+1 weeks after completion of the third cycle of CHT (approximately 13+1 weeks after randomization). Then CHT will be re-administered 5+1 weeks after surgery.
- post-operative CHT (Arm B) (Type: ACTIVE_COMPARATOR): In post-operative CHT arm, surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).
- peri-operative CHT + post-operative CHT-RTX (Arm C) (Type: EXPERIMENTAL): CHT 1 week (+3 days) after randomization surgery after re-staging and 3+1 weeks after completion of the third cycle of CHT CHT 5+1 weeks after surgery.
- post-operative CHT + post-operative CHT-RTX (Arm D) (Type: ACTIVE_COMPARATOR): surgery will take place 3+1 weeks after randomization and CHT will be administered 5+1 weeks after surgery (approximately 8+1 weeks after randomization).

Based on this trial design, predict the completion outcome and termination type (if applicable).